Host-derived osteopontin maintains an acute inflammatory response to suppress early progression of extrinsic cancer cells

International Journal of Cancer

Volumn 131, Issue 2, 2012, Pages 322-333

  Hsieh, Yu Hua ^a   Margaret Juliana, M ^b   Ho, Kang Jey ^c   Kuo, Hui Chien ^a   Van Der Heyde, Henri ^d   Elmets, Craig ^a   Chang, Pi Ling ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

^d La Jolla Infectious Disease Institute   (United States)

Author keywords

acute inflammation; cutaneous squamous cell carcinoma cell line; early cancer cell progression; host derived osteopontin; tumor microenvironment

Indexed keywords

CHEMOATTRACTANT; EDETIC ACID; GAMMA INTERFERON; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOCYTE CHEMOTACTIC PROTEIN 5; OSTEOPONTIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; MACROPHAGE MIGRATION; MOUSE; NONHUMAN; OSTEOPONTIN GENE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKIN CARCINOGENESIS; SKIN CARCINOMA; TUMOR GENE; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; WILD TYPE;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; INFLAMMATION; MICE; MICE, TRANSGENIC; OSTEOPONTIN; TUMOR MICROENVIRONMENT;

EID: 84861589038     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26359     Document Type: Article

References (48)

1. Mbeunkui F, Johann DJ, Jr,. Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol 2009; 63: 571-82.
2. Rittling SR, Chambers AF,. Role of osteopontin in tumour progression. Br J Cancer 2004; 90: 1877-81.
3. Hsieh YH, Juliana MM, Hicks PH, Feng G, Elmets C, Liaw L, Chang PL,. Papilloma development is delayed in osteopontin-null mice: implicating an antiapoptosis role for osteopontin. Cancer Res 2006; 66: 7119-27.
4. Wai PY, Kuo PC,. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 2008; 27: 103-18.
5. Crawford HC, Matrisian LM, Liaw L,. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res 1998; 58: 5206-15.
6. Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF, Senger DR,. Osteopontin expression and distribution in human carcinomas. Am J Pathol 1994; 145: 610-23.
7. Shijubo N, Uede T, Kon S, Maeda M, Segawa T, Imada A, Hirasawa M, Abe S,. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Resp Crit Care Med 1999; 160: 1269-73.
8. Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, Farach-Carson CM, Studer UE, Chung LW,. Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 1999; 5: 2271-7.
9. Devoll RE, Li W, Woods KV, Pinero GJ, Butler WT, Farach-Carson MC, Happonen RP,. Osteopontin (OPN) distribution in premalignant and malignant lesions of oral epithelium and expression in cell lines derived from squamous cell carcinoma of the oral cavity. J Oral Pathol Med 1999; 28: 97-101.
10. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC,. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002; 287: 1671-9.
11. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ,. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004; 10: 184-90.
12. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ,. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. PG-513-21. J Natl Cancer Inst 2002; 94: 513-21.
13. Chang PL, Harkins L, Hsieh YH, Hicks P, Sappayatosok K, Yodsanga S, Swasdison S, Chambers AF, Elmets CA, Ho KJ,. Osteopontin expression in normal skin and non-melanoma skin tumors. J Histochem Cytochem 2008; 56: 57-66.
14. Singhal H, Bautista DS, Tonkin KS, Omalley FP, Tuck AB, Chambers AF, Harris JF,. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997; 3: 605-11.
15. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW,. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001; 7: 4060-6.
16. Koopmann J, Fedarko NS, Jain A, Maitra A, Iacobuzio-Donahue C, Rahman A, Hruban RH, Yeo CJ, Goggins M,. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2004; 13: 487-91.
17. Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF,. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 2002; 95: 506-12.
18. Moye VE, Barraclough R, West C, Rudland PS,. Osteopontin expression correlates with adhesive and metastatic potential in metastasis-inducing DNA-transfected rat mammary cell lines. Br J Cancer 2004; 90: 1796-802.
19. Allan AL, George R, Vantyghem SA, Lee MW, Hodgson NC, Engel CJ, Holliday RL, Girvan DP, Scott LA, Postenka CO, Al-Katib W, Stitt LW, et al. Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol 2006; 169: 233-46.
20. Tunio GM, Hirota S, Nomura S, Kitamura Y,. Possible relation of osteopontin to development of psammoma bodies in human papillary thyroid cancer. Arch Pathol Lab Med 1998; 122: 1087-90.
21. Hoshi N, Sugino T, Suzuki T,. Regular expression of osteopontin in granular cell tumor: distinctive feature among Schwannian cell tumors. Pathol Int 2005; 55: 484-90.
22. Hsieh YH, Juliana MM, Chang PL,. Establishment and characterization of an osteopontin-null cutaneous squamous cell carcinoma cell line. In Vitro Cell Dev Biol Anim 2010; 46: 87-91.
23. Rittling SR, Chen Y, Feng F, Wu Y,. Tumor-derived osteopontin is soluble, not matrix associated. J Biol Chem 2002; 277: 9175-82.
24. Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BL,. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest 1998; 101: 1468-78.
25. McGarrity GJ, Steiner T, Vanaman V,. Detection of mycoplasma infection of cell cultures by DNA fluorochrome staining. In:, Tully JG, Razin E, eds. Methods in mycoplasmologyed, vol. II. New York: Academic Press, 1983. 155-208.
26. Oyama T, Sano T, Hikino T, Xue Q, Iijima K, Nakajima T, Koerner F,. Microcalcifications of breast cancer and atypical cystic lobules associated with infiltration of foam cells expressing osteopontin. Virchows Arch 2002; 440: 267-73.
27. Anderberg C, Li H, Fredriksson L, Andrae J, Betsholtz C, Li X, Eriksson U, Pietras K,. Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts. Cancer Res 2009; 69: 369-78.
28. Nau GJ, Liaw L, Chupp GL, Berman JS, Hogan BL, Young RA,. Attenuated host resistance against Mycobacterium bovis BCG infection in mice lacking osteopontin. Infect Immun 1999; 67: 4223-30.
29. Bruemmer D, Collins AR, Noh G, Wang W, Territo M, Arias-Magallona S, Fishbein MC, Blaschke F, Kintscher U, Graf K, Law RE, Hsueh WA,. Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest 2003; 112: 1318-31.
30. Persy VP, Verhulst A, Ysebaert DK, De Greef KE, De Broe ME,. Reduced postischemic macrophage infiltration and interstitial fibrosis in osteopontin knockout mice. Kidney Int 2003; 63: 543-53.
31. Giachelli CM, Lombardi D, Johnson RJ, Murry CE, Almeida M,. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol 1998; 152: 353-8.
32. Hur EM, Youssef S, Haws ME, Zhang SY, Sobel RA, Steinman L,. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol 2007; 8: 74-83.
33. Koh A, da Silva AP, Bansal AK, Bansal M, Sun C, Lee H, Glogauer M, Sodek J, Zohar R,. Role of osteopontin in neutrophil function. Immunology 2007; 122: 466-75.
34. Marcondes MC, Poling M, Watry DD, Hall D, Fox HS,. In vivo osteopontin-induced macrophage accumulation is dependent on CD44 expression. Cell Immunol 2008; 254: 56-62.
35. Banerjee A, Apte UM, Smith R, Ramaiah SK,. Higher neutrophil infiltration mediated by osteopontin is a likely contributing factor to the increased susceptibility of females to alcoholic liver disease. J Pathol 2006; 208: 473-85.
36. Feng F, Rittling SR,. Mammary tumor development in MMTV-c-myc/MMTV-v-Ha- ras transgenic mice is unaffected by osteopontin deficiency. Breast Cancer Res Treatment 2000; 63: 71-9.
37. Oleksowicz L, Dutcher JP,. A review of the new cytokines: IL-4, IL-6, IL-11, and IL-12. Am J Ther 1994; 1: 107-15.
38. Wolk K, Kunz S, Asadullah K, Sabat R,. Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol 2002; 168: 5397-402.
39. Buback F, Renkl AC, Schulz G, Weiss JM,. Osteopontin and the skin: multiple emerging roles in cutaneous biology and pathology. Exp Dermatol 2009; 18: 750-9.
40. Nystrom T, Duner P, Hultgardh-Nilsson A,. A constitutive endogenous osteopontin production is important for macrophage function and differentiation. Exp Cell Res 2007; 313: 1149-60.
41. Burdo TH, Wood MR, Fox HS,. Osteopontin prevents monocyte recirculation and apoptosis. J Leukoc Biol 2007; 81: 1504-11.
42. Scatena M, Almeida M, Chaisson ML, Fausto N, Nicosia RF, Giachelli CM,. NF-κB mediates αvβ3 integrin-induced endothelial cell survival. J Cell Biol 1998; 141: 1083-93.
43. Hedley BD, Welch DR, Allan AL, Al-Katib W, Dales DW, Postenka CO, Casey G, Macdonald IC, Chambers AF,. Downregulation of osteopontin contributes to metastasis suppression by breast cancer metastasis suppressor 1. Int J Cancer 2008; 123: 526-34.
44. Bourassa B, Monaghan S, Rittling SR,. Impaired anti-tumor cytotoxicity of macrophages from osteopontin-deficient mice. Cell Immunol 2004; 227: 1-11.
45. Heilmann K, Hoffmann U, Witte E, Loddenkemper C, Sina C, Schreiber S, Hayford C, Holzlohner P, Wolk K, Tchatchou E, Moos V, Zeitz M, et al. Osteopontin as two-sided mediator of intestinal inflammation. J Cell Mol Med 2009; 6: 1162-74.
46. Schack L, Stapulionis R, Christensen B, Kofod-Olsen E, Skov Sorensen UB, Vorup-Jensen T, Sorensen ES, Hollsberg P,. Osteopontin enhances phagocytosis through a novel osteopontin receptor, the αXβ2 integrin. J Immunol 2009; 182: 6943-50.
47. Pedraza CE, Nikolcheva LG, Kaartinen MT, Barralet JE, McKee MD,. Osteopontin functions as an opsonin and facilitates phagocytosis by macrophages of hydroxyapatite-coated microspheres: implications for bone wound healing. Bone 2008; 43: 708-16.
48. Furger KA, Menon RK, Tuckl AB, Bramwelll VH, Chambers AF,. The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 2001; 1: 621-32.